Once weekly diabetes treatment promising in first Phase III trial

A new long-acting incretin mimetic under development for adjunctive therapy of type II diabetes has met its primary end point in a Phase III study.

Taspoglutide, like other GLP-1 analogues, is administered by subcutaneous injection.
Taspoglutide, like other GLP-1 analogues, is administered by subcutaneous injection.

Taspoglutide, which was discovered by Ipsen and subsequently licensed to Roche, is an analogue of glucagon-like peptide (GLP-1). This incretin hormone lowers blood glucose levels by regulating the secretion of insulin and glucagon.

Unlike the two currently approved GLP-1 analogues liraglutide (Victoza) and exenatide (Byetta), which must be given daily, taspoglutide is a weekly treatment.

The open-label T-EMERGE 2 trial tested weekly taspoglutide injections against twice daily injections of exenatide in 1189 patients with poor glycaemic control despite receiving metformin and/or a glitazone.

After 24 weeks, participants who were randomised to receive add-on treatment with taspoglutide exhibited a greater reduction in glycated haemoglobin level than those who were randomised to receive add-on therapy with exenatide.

Taspoglutide was generally well tolerated. Nausea and vomiting were the most commonly reported adverse events.

Roche plans to test taspoglutide in a total of 8 Phase III trials in more than 6000 patients.

To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases